Since the arrival of the novel coronavirus, lupus and the most prescribed drug used to treat it – hydroxychloroquine – have been thrust into the public spotlight despite the mounting scientific evidence that drug does not appear to improve clinical outcomes in patients with COVID-19. What has been talked about less is what the impact and burden of COVID-19 have been on people with lupus.
- What parallels exist in the overreactive immune response seen in lupus and COVID-19?
- Are people with lupus more or less at risk for COVID-19?
- Are medications used by people with lupus more or less effective in COVID-19?
Diving deep on research on behalf of the lupus community during this crisis, the Lupus Research Alliance (LRA) and Lupus Therapeutics (an affiliate of the LRA) will discuss actions taken to better understand these and other questions. Top physicians on the frontlines will share important new information. Join our next live webinar to learn the latest.
Date: Thursday, May 21, 6:00 pm EDT start
Join Us: Live Zoom Webcast– Register Here
Teo Staeva, PhD, LRA Chief Scientific Officer will provide introductory remarks and moderate the discussion.
Gary Koretzky, MD, PhD, Vice Provost for Academic Integration, Cornell University, Professor of Medicine at Weill Cornell Medicine, and Chair, LRA Scientific Advisory Board will review actions by the LRA and 18 experts to ensure hydroxychloroquine supplies for the community by the FDA and other government and health organizations and, release preliminary results from a new survey regarding the hydroxychloroquine situation among people with lupus in the U.S.
Roberto Caricchio, MD, Professor of Medicine, Chief of Rheumatology and Lupus Program Director at Temple University and LRA-funded investigator will describe the commonalities and differences in the overreactive immune response seen in lupus and severe COVID-19 plus share insights about treating hundreds of COVID-19 patients.
Milena Gianfrancesco, PhD, MPH, Assistant Professor of Medicine, UCSF will discuss findings and updates on the ACR COVID-19 Global Rheumatology Registry and a recent paper examining factors associated with hospitalization of 600 people with rheumatic diseases, including lupus, diagnosed with COVID-19.
Amr H. Sawalha, MD, Chief of the Division of Pediatric Rheumatology, Director of Lupus Center of Excellence, University of Pittsburgh and LRA-funded investigator will explain why people with lupus may be genetically more predisposed to COVID-19 but also interestingly, how control of a specific gene (ACE2) might lead to a COVID-19 prevention therapy.
Albert Roy, Executive Director, Lupus Therapeutics will discuss an observational study that will evaluate within the Lupus Clinical Investigators Network (LuCIN) the prevalence and burden of COVID-19 among people with lupus and examine if the pre-pandemic prescription of anti-malarials and anti-inflammatory therapies reduced, worsened or affected outcomes. This will be examined in relationship to the home environment, social habits, and occupational experience of people with lupus.
Date: Thursday, May 21, 2020
Time: 6:00 pm EST
Webcast: Register Here